Kowa Company Limited

Juridical Foundation the Chemo-sero-therapeutic Research Institute

The Chemo-sero-therapeutic Research Institute

Tomoyuki Koshi

Yoshinori Kyotani

Hiromichi Shigyo

Takahiro Kitamura

Masao Ohkuchi

Hideo Yoshizaki

Kyoko Yasuoka

Seiichi Sato

Junko Totsuka

Takayuki Matsuda

Shunji Takemura

Kyoko Kotaki

Natsuyo Kumai

Tadaaki Ohgiya

Toshihiro Nakashima

Toshiyuki Edano

Tsukasa Nishihara

Takumi Sasaki

Atsuko Sakata

Yuriko Habata

Masahiro Tamura

Yukiyoshi Yamazaki

Soichi Oda

Kazuhiko Kimachi

Toshimi Mizoguchi

Sumiyo Takemoto

Shigeki Kuwata

Tomoko Furuyama

Tsukasa c/o Juridical Foundation The Nishihara

Sumiyo c/o Juridical Foundation The Takemoto

Toshihiro c/o Juridical Foundation The Nakashima

Takumi c/o Juridical Foundation The Sasaki

Takumi c/o Juridical Foundation Sasaki

Toshihiro c/o Juridical Foundation Nakashima

Kazuhiko c/o Juridical Foundation Kimachi

Shigeki c/o Juridical Foundation Kuwata

Tsukasa c/o Juridical Foundation Nishihara

A novel prophylactic/remedy for immunopathy is provided which is not neutralized by a neutralizing antibody to Staphylococcal enterotoxin B (SEB), known as one of superantigens, and may effectively act as a superantigen. A modified SEB having a reduced reactivity with a neutralizing antibody to SEB (anti-SEB antibody) and a prophylactic/remedy for immunopathy comprising as an active ingredient said modified SEB. The modified SEB of the present invention may be prepared with the evolutionary molecular engineering technique by introducing amino acid substitution in the amino acid sequence of SEB, especially at an epitope recognition site of the anti-SEB antibody in the amino acid sequence of SEB.

Modified SEB and prophylactics/remedies for immunopathy containing the same

A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.

Protease-resistant modified SEB and vaccine containing the same

The present invention is directed to a compound represented by formula (1): (wherein Rrepresents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and each of Rand Rrepresents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or Rand Rform, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-&#x3b1;) production inhibitory effect and improved absorption upon oral administration.

Benzofuran derivative

A phenylpyridazine derivative represented by the formula (1): Wherein, R1, R2, R3, X, Y, Z and n have the same meaning as defined in the specification; or a salt thereof, or a medicine containing the compound. The present invention provides water-soluble phenylpyridazine derivatives and medicines containing them, which have excellent inhibitory activity against interleukin-&#x3b2; production, high water solubility and high oral absorbability.

Water-soluble phenylpyridazine derivative and medicine containing the same

Compounds having the formula (1): wherein Rrepresents an alkyl or alkenyl group, Rand Reach independently represent a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or Rand Rmay be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represent a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to medicinal compositions containing them. These compounds have inhibitory activity against IL-1&#x3b2; production, high water solubility and good oral absorbability.

Water-soluble phenylpyridazine compounds and compositions containing the same

Compounds having the formula (1):wherein Rrepresents an alkyl or alkenyl group, Rand Reach independently represent a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or Rand Rmay be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represent a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to medicinal compositions containing them. These compounds have inhibitory activity against IL-1&#x3b2; production, high water solubility and good oral absorbability.

Compounds having the formula (1):wherein Rrepresents an alkyl or alkenyl group, Rand Reach independently represents a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or Rand Rmay be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represents a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to pharmaceutical compositions containing them. These compounds have inhibitory activity against IL-1&#x3b2; production, high water solubility and good oral absorbability.

Pyridazin-3-one derivatives and medicines containing the same

Phenylpyridazine compounds and medicines containing the same

Pyridazine derivatives and drugs containing the same as the active ingredient

Pyridazine compounds and compositions containing the same

Growing community of inventors

Shiki, Japan

Tomoyuki Koshi